Department of Anesthesiology and Pain Medicine, University of Washington Medical Center, Seattle, WA 98195-6540, USA.
Reg Anesth Pain Med. 2012 Sep-Oct;37(5):508-14. doi: 10.1097/AAP.0b013e318259ce35.
The transversus abdominis plane (TAP) block is an established technique to manage post-cesarean delivery pain. Transversus abdominis plane blocks with a local anesthetic only offer no analgesic benefits compared with intrathecal morphine. Adjuvants to extend TAP block duration and possibly reduce wound hyperalgesia, known to be a risk factor for chronic pain, have not been studied. We hypothesized that a TAP block with clonidine will affect postsurgical wound hyperalgesia and improve pain outcomes.
Ninety women were randomly assigned to receive 1 of 3 TAP blocks after cesarean delivery: saline (placebo), bupivacaine (BupTAP), or bupivacaine + clonidine (CloTAP). The primary outcome was wound hyperalgesia index at 48 hours. Secondary outcomes included pain scores, analgesic consumption, and pain descriptors up to 12 months.
Wound hyperalgesia index at 48 hours (median [25th-75th percentiles]) was 1.07 (0.48-3.26) in the placebo group, 1.27 (0.59-2.95) in the BupTAP group, and 0.74 (0.09-2.25) in the CloTAP group (P = 0.48). Morphine request in the postanesthesia care unit was significantly higher in the placebo group compared with the other TAP groups (P = 0.01). Postoperative pain scores and requests for breakthrough medication at 48 hours (30% in the placebo group, 24% in the BupTAP group, and 12% in the CloTAP group, P = 0.25) or chronic pain descriptors reported up to 12 months did not differ significantly among groups.
Adding clonidine to a TAP block with bupivacaine did not affect wound hyperalgesia index and it did not improve short-term or long-term pain scores in women undergoing elective cesarean delivery. Further studies are warranted to determine the benefits of antihyperalgesic adjuvants in TAP solutions for specific individuals at risk for chronic pain.
腹横肌平面(TAP)阻滞是一种用于管理剖宫产术后疼痛的成熟技术。与鞘内吗啡相比,仅使用局部麻醉剂的 TAP 阻滞没有镇痛益处。尚未研究延长 TAP 阻滞持续时间并可能减少伤口痛觉过敏的佐剂,已知伤口痛觉过敏是慢性疼痛的一个风险因素。我们假设氯胺酮 TAP 阻滞将影响术后伤口痛觉过敏并改善疼痛结局。
90 名女性随机分配接受剖宫产术后 1 种 TAP 阻滞中的 1 种:生理盐水(安慰剂)、布比卡因(BupTAP)或布比卡因+氯胺酮(CloTAP)。主要结局是 48 小时时的伤口痛觉过敏指数。次要结局包括 12 个月内的疼痛评分、镇痛药物消耗和疼痛描述符。
48 小时时的伤口痛觉过敏指数(中位数[25%分位数-75%分位数])为安慰剂组 1.07(0.48-3.26)、BupTAP 组 1.27(0.59-2.95)和 CloTAP 组 0.74(0.09-2.25)(P=0.48)。与其他 TAP 组相比,麻醉后护理单元中安慰剂组的吗啡需求明显更高(P=0.01)。术后 48 小时时的疼痛评分和突破性药物请求(安慰剂组 30%、BupTAP 组 24%和 CloTAP 组 12%,P=0.25)或 12 个月内报告的慢性疼痛描述符在组间无显著差异。
在布比卡因 TAP 阻滞中加入氯胺酮并未影响伤口痛觉过敏指数,也未改善接受选择性剖宫产的女性的短期或长期疼痛评分。需要进一步的研究来确定 TAP 溶液中抗痛觉过敏佐剂对特定慢性疼痛风险个体的益处。